Literature DB >> 22101800

Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.

Boris Guiu1, Elodie Crevisy-Girod, Christine Binquet, Laurence Duvillard, David Masson, Côme Lepage, Samia Hamza, Denis Krausé, Bruno Verges, Anne Minello, Jean-Pierre Cercueil, Patrick Hillon, Jean-Michel Petit.   

Abstract

OBJECTIVES: The SteatoTest, fatty liver index (FLI) and hepatic steatosis index (HSI) are clinico-biological scores of steatosis validated in general or selected populations. Serum adiponectin (s-adiponectin) and retinol binding protein 4 (s-RBP4) are adipokines that could predict liver steatosis. We investigated whether the Steatotest, FLI, HSI, s-adiponectin and s-RBP4 could be valid predictors of liver steatosis in type-2 diabetic (T2D) patients.
METHODS: We enrolled 220 consecutive T2D patients. Reference standard was 3.0 T (1)H-MR spectroscopy (corrected for T1 and T2 decays). Intraclass correlation coefficients (ICCs), Kappa statistic measures of agreement, receiver operating characteristic (ROC) curves were assessed.
RESULTS: Median liver fat content was 91 mg triglyceride/g liver tissue (range: 0-392). ICCs among the Steatotest, FLI, HSI, s-adiponectin, s-RBP4 and spectroscopy were low: 0.384, 0.281, 0.087, -0.297 and 0.048. Agreement between scores and spectroscopy was poor (Kappa range: 0.042-0.281). The areas under the ROC curves were low: 0.674, 0.647, 0.637, 0.616 and 0.540. S-adiponectin and s-RBP4 levels were strongly related to the presence of diabetic nephropathy (P = 0.0037 and P = 0.004; Mann-Whitney).
CONCLUSION: The SteatoTest, FLI, HSI, s-adiponectin, s-RBP4 are not valid predictors of steatosis in T2D patients. Clino-biological markers cannot replace (1)H-MR spectroscopy for the assessment of liver fat in this population. KEY POINTS: (1) H-MR spectrosopy can reliably estimate the weight fraction of liver steatosis. Type-2 diabetes provides an interesting model for assessing liver steatosis. Clinico-biological markers seem to be invalid predictors for steatosis in type-2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22101800     DOI: 10.1007/s00330-011-2326-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  40 in total

1.  Assessing kidney function--measured and estimated glomerular filtration rate.

Authors:  Lesley A Stevens; Josef Coresh; Tom Greene; Andrew S Levey
Journal:  N Engl J Med       Date:  2006-06-08       Impact factor: 91.245

2.  Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects.

Authors:  Anna Kotronen; Leena Juurinen; Antti Hakkarainen; Jukka Westerbacka; Anja Cornér; Robert Bergholm; Hannele Yki-Järvinen
Journal:  Diabetes Care       Date:  2007-10-12       Impact factor: 19.112

3.  Mapping of liver fat with triple-echo gradient echo imaging: validation against 3.0-T proton MR spectroscopy.

Authors:  Boris Guiu; Romaric Loffroy; Jean-Michel Petit; Serge Aho; Douraied Ben Salem; David Masson; Patrick Hillon; Jean-Pierre Cercueil; Denis Krause
Journal:  Eur Radiol       Date:  2009-02-27       Impact factor: 5.315

4.  The relationships of plasma adiponectin with a favorable lipid profile, decreased inflammation, and less ectopic fat accumulation depend on adiposity.

Authors:  Konstantinos Kantartzis; Killian Rittig; Bernd Balletshofer; Jürgen Machann; Fritz Schick; Katarina Porubska; Andreas Fritsche; Hans-Ulrich Häring; Norbert Stefan
Journal:  Clin Chem       Date:  2006-08-17       Impact factor: 8.327

5.  Within- and between-subject variation in commonly measured anthropometric and biochemical variables.

Authors:  A Widjaja; R J Morris; J C Levy; K N Frayn; S E Manley; R C Turner
Journal:  Clin Chem       Date:  1999-04       Impact factor: 8.327

Review 6.  Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance.

Authors:  Nina F Schwenzer; Fabian Springer; Christina Schraml; Norbert Stefan; Jürgen Machann; Fritz Schick
Journal:  J Hepatol       Date:  2009-06-11       Impact factor: 25.083

7.  Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy.

Authors:  Jun Koshimura; Hiroki Fujita; Takuma Narita; Takashi Shimotomai; Mihoko Hosoba; Naomi Yoshioka; Masafumi Kakei; Hiromi Fujishima; Seiki Ito
Journal:  Biochem Biophys Res Commun       Date:  2004-03-26       Impact factor: 3.575

8.  Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk.

Authors:  J Westerbacka; A Cornér; M Tiikkainen; M Tamminen; S Vehkavaara; A-M Häkkinen; J Fredriksson; H Yki-Järvinen
Journal:  Diabetologia       Date:  2004-07-28       Impact factor: 10.122

9.  Serum retinol binding protein 4 and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.

Authors:  Haiya Wu; Weiping Jia; Yuqian Bao; Junxi Lu; Jiehua Zhu; Ren Wang; Yaqing Chen; Kunsan Xiang
Journal:  Diabetes Res Clin Pract       Date:  2007-09-29       Impact factor: 5.602

10.  Java-based graphical user interface for the MRUI quantitation package.

Authors:  A Naressi; C Couturier; J M Devos; M Janssen; C Mangeat; R de Beer; D Graveron-Demilly
Journal:  MAGMA       Date:  2001-05       Impact factor: 2.533

View more
  9 in total

Review 1.  Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease.

Authors:  Marianthi Papagianni; Areti Sofogianni; Konstantinos Tziomalos
Journal:  World J Hepatol       Date:  2015-04-08

Review 2.  Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis.

Authors:  Jia-Zhen Zhang; Jing-Jing Cai; Yao Yu; Zhi-Gang She; Hongliang Li
Journal:  Gene Expr       Date:  2019-04-22

3.  Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy.

Authors:  Thomas Karlas; David Petroff; Nikita Garnov; Stephan Böhm; Hannelore Tenckhoff; Christian Wittekind; Manfred Wiese; Ingolf Schiefke; Nicolas Linder; Alexander Schaudinn; Harald Busse; Thomas Kahn; Joachim Mössner; Thomas Berg; Michael Tröltzsch; Volker Keim; Johannes Wiegand
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

Review 4.  Liver fat: a relevant target for dietary intervention? Summary of a Unilever workshop.

Authors:  Harry P F Peters; Patrick Schrauwen; Petra Verhoef; Christopher D Byrne; David J Mela; Andreas F H Pfeiffer; Ulf Risérus; Frits R Rosendaal; Vera Schrauwen-Hinderling
Journal:  J Nutr Sci       Date:  2017-05-08

Review 5.  Nonalcoholic fatty liver disease: Evolving paradigms.

Authors:  Amedeo Lonardo; Fabio Nascimbeni; Mauro Maurantonio; Alessandra Marrazzo; Luca Rinaldi; Luigi Elio Adinolfi
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

6.  Habitual Fructose Intake Relates to Insulin Sensitivity and Fatty Liver Index in Recent-Onset Type 2 Diabetes Patients and Individuals without Diabetes.

Authors:  Katharina S Weber; Marie-Christine Simon; Klaus Strassburger; Daniel F Markgraf; Anette E Buyken; Julia Szendroedi; Karsten Müssig; Michael Roden
Journal:  Nutrients       Date:  2018-06-15       Impact factor: 5.717

7.  Validation of fatty liver index and hepatic steatosis index for screening of non-alcoholic fatty liver disease in adults with obstructive sleep apnea hypopnea syndrome.

Authors:  Li-Da Chen; Jie-Feng Huang; Qing-Shi Chen; Guo-Fu Lin; Hui-Xue Zeng; Xiao-Fen Lin; Xue-Jun Lin; Li Lin; Qi-Chang Lin
Journal:  Chin Med J (Engl)       Date:  2019-11-20       Impact factor: 2.628

8.  Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance.

Authors:  Sabine Kahl; Klaus Straßburger; Bettina Nowotny; Roshan Livingstone; Birgit Klüppelholz; Kathrin Keßel; Jong-Hee Hwang; Guido Giani; Barbara Hoffmann; Giovanni Pacini; Amalia Gastaldelli; Michael Roden
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

9.  Prevalence and predictors of non-alcoholic fatty liver disease as defined by the fatty liver index in a type 2 diabetes population.

Authors:  Cristina Alina Silaghi; Horatiu Silaghi; Horatiu Alexandru Colosi; Anca Elena Craciun; Anca Farcas; Daniel Tudor Cosma; Nicolae Hancu; Raluca Pais; Carmen Emanuela Georgescu
Journal:  Clujul Med       Date:  2016-01-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.